MGI PHARMA to Present at the Merrill Lynch Global Pharmaceutical Biotechnology and Medical Devices Conference
MGI Pharma zu myNews hinzufügen Was ist das?
MGI PHARMA, INC. (Nasdaq:MOGN) today announced that Lonnie
Moulder, President and Chief Executive Officer of MGI PHARMA, will
present at the Merrill Lynch Global Pharmaceutical, Biotechnology and
Medical Devices Conference in London, England on Thursday, September 20,
2007 at 8:00 a.m. ET. Mr. Moulder will provide an overview of the
Company, its products, pipeline and 2007 corporate goals.
The presentation will be webcast live and may be accessed by logging on
to MGI PHARMA’s corporate website at www.mgipharma.com.
Please connect to the Company’s website at
least 15 minutes prior to the live presentation to ensure adequate time
for any software download that may be necessary to listen to the
webcast. An archived version of the presentation will be available
through September 27, 2007.
About MGI PHARMA
MGI PHARMA, INC. is a biopharmaceutical company focused in oncology and
acute care that acquires, researches, develops and commercializes
proprietary products that address the unmet needs of patients. MGI
PHARMA has a portfolio of proprietary pharmaceuticals, and intends to
become a leading biopharmaceutical company. MGI PHARMA markets Aloxi®
(palonosetron hydrochloride) Injection, Dacogen®
(decitabine) for Injection and Gliadel® Wafer
(polifeprosan 20 with carmustine implant) in the United States. The
Company directly markets its products in the U.S. and collaborates with
partners to reach international markets.
